Recombinant coxsackievirus vectors for prevention and therapy of virus-induced heart disease

International Journal of Medical Microbiology

Volumn 298, Issue 1-2, 2008, Pages 127-134

  Henke, Andreas ^a   Jarasch, Nadine ^a   Martin, Ulrike ^a   Wegert, Jenny ^a   Wildner, Anja ^a   Zell, Roland ^a   Wutzler, Peter ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Coxsackievirus B3; Cytokines; Myocarditis; Recombinant virus vectors; Vaccination

Indexed keywords

BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; CD134 ANTIGEN; CYTOKINE; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; INTERLEUKIN 3; OSTEOGENIC PROTEIN 1; RECOMBINANT COXSACKIEVIRUS VECTOR; RECOMBINANT CYTOKINE; TRANSFORMING GROWTH FACTOR BETA3; TUMOR NECROSIS FACTOR SUPERFAMILY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN C; VIRUS RNA; VIRUS VECTOR;

COXSACKIE VIRUS B; COXSACKIE VIRUS B3; ENTEROVIRUS; GENE MUTATION; GENE SEQUENCE; IMMUNE RESPONSE; IMMUNOMODULATION; LETHALITY; MYOCARDITIS; NONHUMAN; RISK FACTOR; SHORT SURVEY; TH1 CELL; TH2 CELL; VIRUS GENOME;

EID: 36749029012     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2007.08.010     Document Type: Short Survey

References (32)

1. Andino R., Silvera D., Suggett S.D., Achacoso P.L., Miller C.J., Baltimore D., and Feinberg M.B. Engineering poliovirus as a vaccine vector for the expression of diverse antigens. Science 265 (1994) 1448-1451
2. Badorff C., Fichtlscherer B., Rhoads R.E., Zeiher A.M., Muelsch A., Dimmeler S., and Knowlton K.U. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: a protective mechanism against enteroviral cardiomyopathy. Circulation 102 (2000) 2276-2281
3. Badorff C., Fichtlscherer B., Muelsch A., Zeiher A.M., and Dimmeler S. Selective delivery of nitric oxide to a cellular target: a pseudosubstrate-coupled dinitrosyl-iron complex inhibits the enteroviral protease 2A. Nitric Oxide 6 (2002) 305-312
4. Chapman N.M., Kim K.S., Tracy S., Jackson J., Hofling K., Leser J.S., Malone J., and Kolbeck P. Coxsackievirus expression of the murine secretory protein interleukin-4 induces increased synthesis of immunoglobulin G1 in mice. J. Virol. 74 (2000) 7952-7962
5. Chow L.H., Gauntt C.J., and McManus B.M. Differential effects of myocarditic variants of coxsackievirus B3 in inbred mice. A pathologic characterization of heart tissue damage. Lab. Invest. 64 (1991) 55-64
6. Feuer R., Mena I., Pagarigan R., Slifka M.K., and Whitton J.L. Cell cycle status affects coxsackievirus replication, persistence, and reactivation in vitro. J. Virol. 76 (2002) 4430-4440
7. Fohlman J., Ilback N.G., Friman G., and Morein B. Vaccination of Balb/c mice against enteroviral mediated myocarditis. Vaccine 8 (1990) 381-384
8. Gauntt C.J., Sakkinen P., Rose N.R., and Huber S.A. Picornaviruses: immunopathology and autoimmunity. In: Cunningham M.W., and Fujinami R.S. (Eds). Effects of Microbes on the Immune System (1999), Lippincott-Raven Publishers, Philadelphia 313-329
9. Geiger K., Howes E., Gallina M., Huang X.J., Travis G.H., and Sarvetnick N. Transgenic mice expressing IFN-gamma in the retina develop inflammation of the eye and photoreceptor loss. Invest. Ophthalmol. Vis. Sci. 35 (1994) 2667-2681
10. Godney E.K., Arizpe H.M., and Gaunti C.J. Characterization of the antibody response in vaccinated mice protected against Coxsackievirus B3-induced myocarditis. Viral Immunol. 1 (1987) 305-314
11. Gravanis M.B., and Sternby N.H. Incidence of myocarditis. A 10-year autopsy study from Malmo, Sweden. Arch. Pathol. Lab. Med. 115 (1991) 390-392
12. Heim A., Grumbach I., Pring-Akerblom P., Stille-Siegener M., Muller G., Kandolf R., and Figulla H.R. Inhibition of coxsackievirus B3 carrier state infection of cultured human myocardial fibroblasts by ribavirin and human natural interferon-alpha. Antiviral Res. 34 (1997) 101-111
13. Henke A., Wagner E., Whitton J.L., Zell R., and Stelzner A. Protection of mice against lethal coxsackievirus B3 infection by using DNA immunization. J. Virol. 72 (1998) 8327-8331
14. Henke A., Zell R., Ehrlich G., and Stelzner A. Expression of immunoregulatory cytokines by recombinant coxsackievirus B3 variants confers protection against virus-caused myocarditis. J. Virol. 75 (2001) 8187-8194
15. Henke A., Zell R., Martin U., and Stelzner A. Direct interferon-gamma-mediated protection caused by a recombinant coxsackievirus B3. Virology 315 (2003) 335-344
16. Henke A., Chiang C.S., Zell R., and Stelzner A. Co-expression of interleukin-2 to increase the efficacy of DNA vaccine-mediated protection in coxsackievirus B3-infected mice. Antiviral Res. 64 (2004) 131-136
17. Horwitz M.S., Evans C.F., McGavern D.B., Rodriguez M., and Oldstone M.B. Primary demyelination in transgenic mice expressing interferon-gamma. Nat. Med. 3 (1997) 1037-1041
18. Horwitz M.S., Krahl T., Fine C., Lee J., and Sarvetnick N. Protection from lethal coxsackievirus-induced pancreatitis by expression of gamma interferon. J. Virol. 73 (1999) 1756-1766
19. Horwitz M.S., La Cava A., Fine C., Rodriguez E., Ilic A., and Sarvetnick N. Pancreatic expression of interferon-gamma protects mice from lethal coxsackievirus B3 infection and subsequent myocarditis. Nat. Med. 6 (2000) 693-697
20. Huber S.A. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice. Lab. Invest. 76 (1997) 691-701
21. Jarasch N., Martin U., Kamphausen E., Zell R., Wutzler P., and Henke A. Interferon-gamma-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3. Viral Immunol. 18 (2005) 355-364
22. Kandolf R., and Hofschneider P.H. Molecular cloning of the genome of a cardiotropic coxsackie B3 virus: full-length reverse-transcribed recombinant cDNA generates infectious virus in mammalian cells. Proc. Natl. Acad. Sci. USA 82 (1985) 4818-4822
23. Kim K.S., Hufnagel G., Chapman N.M., and Tracy S. The group B coxsackieviruses and myocarditis. Rev. Med. Virol. 11 (2001) 355-368
24. Knowlton K.U., Jeon E.S., Berkley N., Wessely R., and Huber S. A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J. Virol. 70 (1996) 7811-7818
25. Mueller S., and Wimmer E. Expression of foreign proteins by poliovirus polyprotein fusion: analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames. J. Virol. 72 (1998) 20-31
26. Porter D.C., Ansardi D.C., Lentz M.R., and Morrow C.D. Expression of poliovirus P3 proteins using a recombinant vaccinia virus results in proteolytically active 3CD precursor protein without further processing to 3Cpro and 3Dpol. Virus Res. 29 (1993) 241-254
27. Saura M., Zaragoza C., McMillan A., Quick R.A., Hohenadl C., Lowenstein J.M., and Lowenstein C.J. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity 10 (1999) 21-28
28. Sin J.I., Sung J.H., Suh Y.S., Lee A.H., Chung J.H., and Sung Y.C. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene. Vaccine 15 (1997) 1827-1833
29. Slifka M.K., Pagarigan R., Mena I., Feuer R., and Whitton J.L. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection. J. Virol. 75 (2001) 2377-2387
30. Tang S., van Rij R., Silvera D., and Andino R. Toward a poliovirus-based Simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity. J. Virol. 71 (1997) 7841-7850
31. Toniolo A., Falcone V., Bernasconi C., Basolo F., Speziale P., and Onodera T. DNA immunization of mice against the VP1 capsid protein of coxsackievirus B4. Scand. J. Immunol. 56 (2002) 448-455
32. Zell R., Markgraf R., Schmidtke M., Gorlach M., Stelzner A., Henke A., Sigusch H.H., and Glück B. Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. Med. Microbiol. Immunol. 193 (2004) 91-100